Skip to content

Study · Not a test of the peptide alone · 1996

4 results

Comparison of cyclic and linear analogs of vasoactive intestinal peptide.

Bolin DR, Cottrell J, Garippa R, Rinaldi N, Senda R, Simko B, O'Donnell M

Drug design and discovery1 Apr 1996Cited by 6 (Europe PMC)

PMID8874048 (opens in a new tab)PepBankPUB-08874048
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Activity measurement

    In guinea pigs, the cyclic VIP analogs showed up to 70-fold increased potency compared with linear compounds.

    In plain wordsIn guinea pigs, ring-shaped VIP analogs were up to 70 times stronger than linear ones.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePotency of cyclic versus linear VIP analogs in vivo
    Study

    guinea pign: not reported in source

    in vivo
    Comparator
    Linear analogs
    Outcome group
    Receptor activity and mechanism · Respiratory

    Measurements

    Potency fold increase
    ≤ 70 fold
    cyclic vs linear compounds

    Source sentences

    Summary
    In vivo, in guinea pigs, the cyclic compounds showed increased potency by up to 70-fold
    1 context sentence
    Summary · context
    A series of i-->i + 4 side-chain to side-chain lactam analogs of vasoactive intestinal peptide has been prepared in order to study the effect of cyclization on biological activity.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Activity measurement

    In guinea pigs, the cyclic VIP analogs significantly enhanced duration of action compared with linear compounds.

    In plain wordsIn guinea pigs, ring-shaped VIP analogs acted for longer than linear ones.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseDuration of action of cyclic versus linear VIP analogs in vivo
    Study

    guinea pign: not reported in source

    in vivo
    Comparator
    Linear analogs
    Outcome group
    Receptor activity and mechanism · Respiratory

    Source sentences

    Summary
    and significantly enhanced duration of action as compared to linear compounds.
    1 context sentence
    Summary · context
    A series of i-->i + 4 side-chain to side-chain lactam analogs of vasoactive intestinal peptide has been prepared in order to study the effect of cyclization on biological activity.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    In guinea pig tracheal smooth muscle and human bronchial tissue, about half of the cyclic VIP analogs were more potent than the linear analogs and about half were less potent.

    In plain wordsIn lab tests on airway tissue, about half of the ring-shaped VIP analogs were stronger than the linear ones and half were weaker.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    MixedPotency of cyclic versus linear VIP analogs in vitro
    Study

    guinea pig and humann: not reported in source

    guinea pig tracheal smooth muscle and human bronchial tissue
    Comparator
    Linear analogs
    Outcome group
    Receptor activity and mechanism · Respiratory

    Source sentences

    Summary
    In vitro, on guinea pig tracheal smooth muscle and on human bronchial tissue, approximately half of the cyclic analogs showed increased potency and half were decreased over the linear analogs.
    1 context sentence
    Summary · context
    A series of i-->i + 4 side-chain to side-chain lactam analogs of vasoactive intestinal peptide has been prepared in order to study the effect of cyclization on biological activity.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    In airway tissue in vitro, several cyclic VIP analogs were 10- to 20-fold more potent than the linear species, and one was 290-fold more potent.

    In plain wordsIn lab tests on airway tissue, some ring-shaped VIP analogs were 10 to 20 times stronger than linear ones, and one was 290 times stronger.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseFold potency gain of the most potent cyclic analogs in vitro
    Study

    guinea pig and humann: not reported in source

    guinea pig tracheal smooth muscle and human bronchial tissue
    Comparator
    Linear analogs
    Outcome group
    Receptor activity and mechanism · Respiratory

    Measurements

    Potency fold increase
    10 to 20 fold
    several cyclic compounds vs linear species
    Potency fold increase
    290 fold
    one cyclic compound vs linear species

    Source sentences

    Summary
    Several cyclic compounds were between 10- and 20-fold more potent and one was 290-fold more potent than the linear species.
    1 context sentence
    Summary · context
    A series of i-->i + 4 side-chain to side-chain lactam analogs of vasoactive intestinal peptide has been prepared in order to study the effect of cyclization on biological activity.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.